What are the diagnostic criteria for opioid-induced hyperalgesia (OIH)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Identifying opioid-induced hyperalgesia (OIH) requires careful assessment of pain patterns that paradoxically worsen despite increasing opioid doses, as evidenced by the most recent study in 2018 1. To identify OIH, look for key signs including:

  • Pain that becomes more diffuse or extends beyond the original site
  • Increased pain sensitivity (allodynia)
  • Pain that worsens with dose escalation
  • Diminishing analgesic effects despite higher doses Patients may report that the pain feels different in quality compared to their original pain. It is essential to differentiate OIH from tolerance, as tolerance typically improves with dose increases while OIH worsens, as noted in a study published in the Annual Review of Medicine 1. Management involves:
  • Gradually tapering the current opioid
  • Possibly rotating to a different opioid like methadone or buprenorphine
  • Adding adjuvant medications such as ketamine, gabapentinoids, or NSAIDs
  • Implementing non-pharmacological pain management strategies OIH occurs because prolonged opioid exposure can cause neuroplastic changes in the central nervous system, including NMDA receptor activation and increased production of excitatory neurotransmitters, which paradoxically amplify pain signaling pathways, as discussed in a study published in the Annals of Internal Medicine 1. Early recognition is crucial as continuing to increase opioid doses will exacerbate rather than relieve the patient's pain, highlighting the importance of careful assessment and management of OIH, as supported by the most recent evidence 1.

From the Research

Identifying Opioid-Induced Hyperalgesia

To identify if somebody has opioid-induced hyperalgesia (OIH), the following points should be considered:

  • OIH is a state of nociceptive sensitization caused by exposure to opioids, leading to a paradoxical response where a patient receiving opioids for pain treatment becomes more sensitive to certain painful stimuli 2.
  • Clinical features of OIH can be observed in patients of both sexes, all ages, and with various types of pain treated with different classes of opioids 3.
  • OIH can be diagnosed clinically, and its symptoms can be resolved when the condition is diagnosed and managed 3.
  • Key signs that may indicate OIH include:
    • Unexplained pain reports or diffuse allodynia unassociated with the original pain
    • Increased levels of pain with increasing dosages of opioids
    • Waning effect of opioid treatment in the absence of disease progression 2

Mechanisms and Risk Factors

The mechanisms of OIH are thought to be multifactorial, involving:

  • Medullary descending pathways 4
  • Central glutaminergic system 2
  • Spinal dynorphins 2, 5
  • Descending facilitation from the rostral ventromedial medulla 5
  • N-methyl-D-aspartate (NMDA) receptors 2, 6, 5 Patient risk factors, opioid mitigation, and both pharmacologic and non-pharmacologic strategies should be considered to prevent OIH 4.

Diagnosis and Differentiation

It is crucial for clinicians to differentiate amongst clinically worsening pain, tolerance, and OIH, as the treatment of these conditions differs 5. A suggested clinical definition and directions for clinical differentiation of OIH from other diagnoses can be used to guide diagnosis 4.

Treatment Options

Treatment options for OIH include:

  • Reducing the opioid dosage or tapering them off 2
  • Opioid rotation 3, 5
  • Supplementation with NMDA receptor modulators 2
  • Use of adjuvant pharmacotherapies, such as ketamine and dexmedetomidine 3
  • Office-based detoxification 5
  • Sublingual buprenorphine 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.